MX173793B - El uso de fenilpropanolamina en la preparacion de composiciones para inducir la descongestion nasal y la secrecion de moco en las vias aereas superiores - Google Patents

El uso de fenilpropanolamina en la preparacion de composiciones para inducir la descongestion nasal y la secrecion de moco en las vias aereas superiores

Info

Publication number
MX173793B
MX173793B MX025860A MX2586091A MX173793B MX 173793 B MX173793 B MX 173793B MX 025860 A MX025860 A MX 025860A MX 2586091 A MX2586091 A MX 2586091A MX 173793 B MX173793 B MX 173793B
Authority
MX
Mexico
Prior art keywords
secretion
preparation
deconestion
moco
phenylpropanolamine
Prior art date
Application number
MX025860A
Other languages
English (en)
Inventor
Roger John Phipps
Original Assignee
Norwich Eaton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norwich Eaton Pharma filed Critical Norwich Eaton Pharma
Publication of MX173793B publication Critical patent/MX173793B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a el uso de d(+)-norefredina, 1(-)-norefredrina o mezclas de las mismas, en la preparación de una composición oral para inducir tanto descongestión nasal y secreción de moco en ls vías aereas superiores de una persona que padece sinusitis u otitits media caracterizada por congestión respiratoria superior y retención de secreción respiratorias espesas, dichas composición estando caracterizada porque comprende una cantidad segura y efectiva de 1(-)-norefedrina y una base de excipiente farmaceuticamente aceptable.
MX025860A 1990-05-21 1991-05-20 El uso de fenilpropanolamina en la preparacion de composiciones para inducir la descongestion nasal y la secrecion de moco en las vias aereas superiores MX173793B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52621890A 1990-05-21 1990-05-21

Publications (1)

Publication Number Publication Date
MX173793B true MX173793B (es) 1994-03-25

Family

ID=24096426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX025860A MX173793B (es) 1990-05-21 1991-05-20 El uso de fenilpropanolamina en la preparacion de composiciones para inducir la descongestion nasal y la secrecion de moco en las vias aereas superiores

Country Status (10)

Country Link
EP (1) EP0530311A1 (es)
JP (1) JPH05509300A (es)
AU (2) AU7992091A (es)
CA (1) CA2083403A1 (es)
IE (1) IE911711A1 (es)
IL (1) IL98179A0 (es)
MX (1) MX173793B (es)
PT (1) PT97730A (es)
WO (1) WO1991017746A1 (es)
ZA (1) ZA913831B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH069382A (ja) * 1992-04-17 1994-01-18 Takeda Chem Ind Ltd 安定化された固型製剤およびその製造方法
ES2065846B1 (es) * 1993-04-20 1995-10-01 Cusi Lab Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
AU676315B2 (en) * 1993-06-30 1997-03-06 Takeda Chemical Industries Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
ZA963590B (en) * 1995-05-10 1996-11-19 Adcock Ingram Ltd Pharmaceutical composition
US6469009B1 (en) * 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
WO1999048483A2 (en) * 1998-03-23 1999-09-30 Warner-Lambert Company (-)-phenylpropanolamine as a sympathomimetic drug
WO2005123052A1 (en) * 2004-06-18 2005-12-29 Jiangsu Hengrui Medicine Co., Ltd. Drug composition containing ambroxol and erdosteine or acetylcysteine
CA2598668A1 (en) * 2005-02-25 2006-09-08 Mutual Pharmaceutical Company, Inc. Dosage forms of antibiotics and combinations of antibiotics and symptomatic relief agents
US9034929B2 (en) 2007-01-12 2015-05-19 Angus Chemical Company Aminoalcohol and biocide compositions for aqueous based systems
CN102026541B (zh) 2008-05-15 2014-03-19 安格斯化学公司 含烃组合物中改善的腐蚀和微生物控制
US8697754B2 (en) 2008-05-15 2014-04-15 Dow Global Technologies Llc Aminoalcohol and biocide compositions for aqueous based systems
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
CA3001337C (en) * 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
CN111346100A (zh) * 2020-04-16 2020-06-30 四川大学华西医院 阿司匹林或其衍生物在制备治疗气道粘液高分泌的药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818541A (en) * 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine

Also Published As

Publication number Publication date
AU2050895A (en) 1995-08-03
WO1991017746A1 (en) 1991-11-28
PT97730A (pt) 1992-02-28
AU7992091A (en) 1991-12-10
ZA913831B (en) 1992-02-26
JPH05509300A (ja) 1993-12-22
CA2083403A1 (en) 1991-11-22
EP0530311A1 (en) 1993-03-10
IL98179A0 (en) 1992-06-21
IE911711A1 (en) 1991-12-04

Similar Documents

Publication Publication Date Title
MX173793B (es) El uso de fenilpropanolamina en la preparacion de composiciones para inducir la descongestion nasal y la secrecion de moco en las vias aereas superiores
BG102689A (bg) Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения
HRP20030951B1 (hr) Formulacije jednodnevnih doza oksikodona
DK0613371T3 (da) Ny kombination af formoterol og budesonid
DK503687D0 (da) Farmaceutisk praeparat af ibuprofen
DK0402950T3 (da) Behandling af postmenopausale ulemper
KR960703009A (ko) 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용
UA29507C2 (uk) Фармацевтична композиція для інгаляції та спосіб її одержання
ATE239482T1 (de) Neue arzneiformulierung
DE60121012D1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
ES554967A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
MXPA02011311A (es) Composicion novedosa.
ES2152966T3 (es) Formas de dosificado farmaceuticas de desleido rapido y procedimiento para su preparacion.
BE902185A (fr) Compositions pour les soins des voies respiratoires.
SE9603669D0 (sv) New combination
EP0220696A3 (en) Use of buspirone for preparing pharmaceutical compositions for alleviation of panic disorders
ES2171440T3 (es) Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal.
DK1009394T3 (da) Ny formulering til inhalering med en ihældt bulkdensitet på fra 0,28 til 0,38 g/ml omfattende formoterol
GR1000419B (el) Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
IL142284A0 (en) A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor
UA37278C2 (uk) Протикашльова фармацевтична композиція для перорального введення
IT9019793A0 (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
IT1241631B (it) "n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono